SRPT Sarepta Therapeutics, Inc.
P/E
--
Forward P/E
6.86
Price/Sales
1.005
Beta
0.205
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Sarepta to Pay REGENXBIO $39.0 Million to Settle Gene Therapy Patent Litigation
Sarepta Therapeutics has entered into a settlement agreement with REGENXBIO Inc. and the University of Pennsylvania (UPenn) to resolve pending patent...
RA Capital Exits Sarepta Therapeutics, Sells $85M Stake
Prominent biotech investor RA Capital Management has liquidated its entire position in Sarepta Therapeutics (SRPT), according to its latest quarterly...